Discover
PEPG
PepGen Inc.
1.81
2 x 1.31
2 x 2.26
bid
ask
+
0.01
0.56%
2 @ 04:00 PM
1.81 +0.00 (0.00%)
| Ytd | -72.20% | |
| 1y | 49.59% |
1.75
day range
1.83
1.01
52 week range
7.80
| Open | 1.80 | Prev Close | 1.80 | Low | 1.75 | High | 1.83 | Mkt Cap | 125.20M |
| Vol | 345.81K | Avg Vol | 885.48K | EPS | -1.46 | P/E | N/A | Forward P/E | -1.45 |
| Beta | 1.76 | Short Ratio | 5.75 | Inst. Own | 96.36% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-12 | 50-d Avg | 1.61 | 200-d Avg | 4.07 | 1yr Est | 15.40 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -0.87 | -0.66 | 0.21 | 24.14% |
| 2024-08-08 | 2024-06 | -0.72 | N/A | N/A | N/A |
| 2024-08-08 | 2024-06 | -0.72 | -0.87 | -0.15 | -20.83% |
| 2024-05-14 | 2024-03 | -0.74 | -0.63 | 0.11 | 14.86% |
| 2024-05-14 | 2024-03 | -0.74 | N/A | N/A | N/A |
| 2024-03-06 | 2023-12 | -1.01 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-18 | B of A Securities | Upgrade | Neutral | Neutral |
| 2024-11-08 | Wedbush | Upgrade | Outperform | Outperform |
| 2024-11-08 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-01 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-07-31 | Wedbush | Upgrade | Outperform | Outperform |
| 2024-05-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-03-23 | GOYAL JAYA | Officer | 0.00 | Sale |
| 2023-11-29 | MCARTHUR JAMES G PH.D. | Chief Executive Officer | 1.69K | Purchase |
| 2024-07-24 | MELLION MICHELLE L | Officer | 0.00 | Sale |
| 2024-02-08 | RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-05-16 | SVENSTRUP NIELS | Officer | 0.00 | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | RA Capital Management, L.P. | 10.69M | 41.58M | 32.79% |
| 2024-09-29 | Janus Henderson Group PLC | 2.34M | 9.09M | 7.17% |
| 2024-09-29 | Suvretta Capital Management, LLC | 1.66M | 6.46M | 5.10% |
| 2024-09-29 | Viking Global Investors, L.P. | 1.48M | 5.77M | 4.55% |
| 2024-09-29 | Perceptive Advisors Llc | 1.41M | 5.49M | 4.33% |
| 2024-09-29 | Adage Capital Partners GP L.L.C. | 1.13M | 4.39M | 3.46% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 492.80K | 1.92M | 1.51% |
| 2024-10-30 | iShares Russell 2000 ETF | 396.78K | 1.54M | 1.22% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 289.48K | 1.13M | 0.89% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 158.99K | 618.45K | 0.49% |
| 2024-10-30 | iShares Russell 2000 Growth ETF | 120.16K | 467.41K | 0.37% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 95.30K | 370.70K | 0.29% |